Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium phosphate, monobasic, monohydrate + sodium phosphate, dibasic, anhydrous is a **combination of two inorganic phosphate salts** used in both oral and intravenous pharmaceutical products. In the oral tablet product **Visicol**, it acts as an **osmotic laxative/purgative** for bowel cleansing before colonoscopy by drawing water into the intestinal lumen and promoting rapid evacuation. In intravenous products marketed as **sodium phosphates injection**, the same salt pair serves as a **parenteral phosphorus replacement** to prevent or correct hypophosphatemia in patients with inadequate oral intake. The combination provides systemic phosphate and sodium rather than acting through a discrete receptor target, and its pharmacology relates to phosphate homeostasis, osmotic fluid shifts, acid-base buffering, and cellular metabolic needs. Oral sodium phosphate products carry a boxed warning for **acute phosphate nephropathy** and require careful hydration and avoidance in at-risk patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium phosphate, monobasic, monohydrate + sodium phosphate, dibasic, anhydrous.